Now I have a good picture. Let me finalize the review:

- Our paper is better than PagFormer (4.25 — parameter tuning on test set, small test sets) and Organ-DETR (4.67 — limited clinical relevance, weaker baselines)
- Comparable to DynaMer (4.75 — MoE-based medical imaging, unclear novelty, limited gains) but with cleaner ablations and larger performance contributions
- Below M4oE (5.75 — accepted, stronger conceptual novelty, broader scope)

My assessment: the paper's empirical work and ablations are solid, but the unvalidated central framing (lesion proposals) and missing backbone baseline keep it from being clearly above the 5.0 threshold. I place it at **5.0**.

---

## Summary
This paper proposes an end-to-end framework for multi-view diabetic retinopathy (DR) grading that generates "lesion proposals" internally via a Grade-Activated Lesion Proposal (GALP) module — using stage-wise auxiliary classifiers and CAM-style evidence maps — and fuses them across views through a Cross-View Lesion Expert Guided Regional Fusion (LGRF) module with gated Mixture-of-Experts and Top-K-weighted cross-view attention. The method is evaluated on two multi-view DR benchmarks (MFIDDR and DRTiD), where the lesion-free variant achieves 83.9% accuracy on MFIDDR, surpassing several externally informed baselines, and 76.0% on DRTiD. Ablations confirm both GALP and LGRF contribute non-trivial gains.

## Strengths
- **Strong empirical performance without external annotations.** On MFIDDR (Table 1), the lesion-free variant (83.9% Acc) surpasses externally informed methods CVSA (82.6%), LFMVDR (82.2%), and SMVDR-W (83.0%), and comes within 0.1pp of SMVDR-M (84.0%). On DRTiD (Table 3), the end-to-end variant (76.0% Acc) exceeds CrossFiT (75.6%), which relies on clinician-annotated OD/macula coordinates.
- **Well-executed ablation study.** Table 4 cleanly isolates module contributions: removing GALP drops accuracy by 1.2pp (83.9→82.7), removing the expert pool drops by 1.3pp (83.9→82.6), and removing LGRF entirely drops by 1.6pp (83.9→82.3). These non-trivial gaps confirm both modules are individually consequential.
- **Comprehensive grade-wise analysis.** Table 2 reveals particular strength on clinically consequential intermediate grades (Grade 2 F1=62.5%, Grade 3 F1=74.1% without lesions), with full per-grade precision/specificity breakdowns enabling granular comparison.
- **Cross-dataset generalization.** The method achieves SOTA on both MFIDDR (four-view, 224×224, ImageNet pretraining) and DRTiD (two-view, 512×512, EyePACS pretraining) without dataset-specific architectural changes, demonstrating robustness to varying imaging protocols.
- **Pragmatic hyperparameter study.** Figure 3 sweeps retention ratio, number of routed experts, and total experts, showing stable performance around chosen defaults with clear degradation at extremes.

## Weaknesses

### Fatal
None.

### Major
- **Lesion proposals are never validated as corresponding to actual lesions.** The paper's entire narrative — title, abstract, contributions, and conclusions — is built on the claim that GALP produces *lesion* proposals serving as surrogates for costly external lesion annotations. However, the paper provides zero evidence that the selected high-activation regions correspond to actual retinal lesions: no qualitative visualizations overlaying proposal regions on fundus images, no quantitative overlap metrics against the available machine-generated lesion masks on MFIDDR, and no clinician evaluation. The method is evaluated only through end-task grading accuracy (Tables 1-4), which cannot distinguish between "the proposals capture lesions" and "the proposals are a useful feature selection mechanism that upweights discriminative non-lesion anatomy." The empirical grading results remain valid, but the central interpretative claim driving the paper is unsubstantiated.
- **Missing bare-bones Swin-B multi-view baseline.** The paper uses Swin-B as backbone (line 208), while all end-to-end baselines in Table 1 use other architectures (ResNet-50, VGG-19, RETFound, etc.). The ablation in Table 4 removes only one module at a time: "w/o GALP" (82.7%) still uses LGRF, and "w/o LGRF" (82.3%) still uses GALP. Neither row isolates what a plain multi-view Swin-B with concatenation and classifier achieves. Without this baseline, the reader cannot determine how much of the 2.4% gain over ETMC (81.5%) is attributable to the proposed modules versus upgrading the backbone architecture.

### Minor
- **Interpretability claimed but not demonstrated.** Contribution 2 (line 44) and Figure 1 claim "superior interpretability" for the method. However, the paper contains no interpretability analysis — no proposal visualizations, no attention map inspection, no case studies. This claim should either be supported or withdrawn.
- **Grade 4 performance gap with CVSA unexamined.** In Table 2, the lesion-free variant's Grade 4 F1 is 36.0%, substantially behind CVSA's 64.1%. While the paper's Grade 4 performance is competitive with or better than most other externally informed methods (WGLIN 29.8%, SMVDR-M 30.4%, LFMVDR 17.0%), the large gap with CVSA on the most clinically severe category warrants discussion.
- **No statistical significance or variance reporting.** All tables and figures report point estimates without standard deviations, confidence intervals, or statistical tests. On DRTiD, the claimed SOTA margin is 0.4% (76.0 vs. 75.6), which could fall within run-to-run noise. While single-run reporting is common in this subfield, it weakens claims of superiority on thin margins.
- **Cyclic adjacent-view pairing lacks justification.** LGRF fuses view i with view i+1 (with N wrapping to 1) but provides no motivation for this cyclic design. Fundus views have specific anatomical relationships that are not obviously cyclic; the choice appears arbitrary without explanation.

### Trivial
None.

## Nice-to-Haves
- **Computational cost analysis.** The method adds auxiliary classifiers at three stages, an MoE with 6 experts, and cross-view attention at multiple stages. Reporting parameter count, inference time, and memory footprint would help assess suitability for clinical deployment.
- **Micro-lesion sensitivity not isolated.** The paper claims recovery of "small, low-contrast lesions" (abstract, contribution 1) but no experiment stratifies performance by lesion size or specifically evaluates microaneurysm detection.
- **Qualitative visualization of proposals.** Overlaying the top-K proposal regions on a few example fundus images would substantially strengthen the paper's narrative, even as a small qualitative study. Computing IoU between proposals and the available machine-generated lesion masks on MFIDDR would similarly add quantitative support.

## Removed Points
These points are flagged to be removed, treat them with caution.

- *Harsh Critic: "The externally informed comparison on MFIDDR uses machine-generated, not clinician-annotated, lesion masks."* — The paper explicitly states (line 185) that MFIDDR's masks are "generated by a segmentation model." This is transparent disclosure, not a hidden weakness. The harsh critic speculates about annotation-quality differences across compared methods but provides no evidence; this is not a verifiable flaw in the paper.
- *Harsh Critic: "Different preprocessing pipelines make cross-dataset generalization claims harder to sustain."* — The paper follows dataset-specific conventions (224×224 for MFIDDR, 512×512 for DRTiD) to be consistent with prior work on each benchmark. This is standard practice, not a weakness.
- *Harsh Critic: "MoE gating conditions on a mean-pooled vector discards spatial information."* — This is a design opinion. Mean pooling is a standard approach for global context in MoE gating and the paper's choice is not inherently wrong.
- *Harsh Critic: "Precision and F1 score listed but specificity is the main per-class metric — unusual combination; rationale not explained."* — This is a nitpick about metric reporting conventions that does not affect the validity of results.
- *Strength Finder: "Higher model interpretability."* — Conflicts with the verified weakness that no interpretability analysis is actually provided. Removed as a strength.

## Novel Insights
None beyond the paper's own contributions. The combination of CAM-based self-derived proposals with gated MoE cross-view fusion is a technically coherent synthesis, but the core ideas (auxiliary classifiers for feature enhancement, CAM for region selection, MoE for fusion) are individually established and their combination here does not reveal fundamentally new principles.

## Suggestions
- **Validate lesion proposals.** On MFIDDR, compute IoU or recall of proposal regions against the available machine-generated lesion masks. On a small subset, overlay proposals on fundus images and have a clinician assess whether they capture lesions. This would transform the paper's central claim from assumption to evidence.
- **Add a plain Swin-B multi-view baseline** (multi-view concatenation + classifier, no GALP, no LGRF) to the ablation table. This single row would resolve the backbone confound and let readers assess how much gain is attributable to the proposed modules.
- **Either support the interpretability claim** with concrete analysis (proposal visualizations, attention inspection, case studies) or remove it from the contribution list and Figure 1.

## Calibration

**Round 1 bracket:** 4.0–6.0 based on comparison with strong-reject (2.33), weak (3.00–4.25), and accept (6.25–6.50) anchors. The paper has solid empirical results and clean ablations but significant framing and baseline gaps.

**Round 2 narrowing:** Compared against DynaMer (4.75, Reject — MoE-based medical imaging, limited novelty, marginal gains), MVG (5.00, Reject — broader scope but similar-level contribution), and M4oE (5.75, Accept — stronger conceptual novelty, better interpretability analysis). The paper is comparable to DynaMer in quality but with cleaner ablations and larger module contributions; it falls clearly below M4oE due to unvalidated central claims and missing baselines.

**Final score: 5.0.** The paper has genuine empirical contributions and well-executed ablations, but the unvalidated framing around "lesion proposals" and the missing backbone baseline prevent it from reaching acceptance threshold despite the solid grading results.

### Anchor comparison summary
| Anchor | Score | Round | Comparison |
|--------|-------|-------|------------|
| MrOefpTvev (TxTN) | 2.33 | R1 | This paper is substantially stronger — has two benchmarks, clean ablations, coherent method |
| EjIKerYk1O (Aircraft) | 2.33 | R1 | N/A — different domain |
| G9HV5upWhx (SgCG) | 2.33 | R1 | This paper has much more complete empirical evaluation |
| PFUrgJtfs0 (Lost in Transf.) | 3.50 | R1 | This paper is stronger — proposes novel method with positive results rather than a dissection |
| Yc4zTbR8no (WaveFormer) | 3.00 | R1 | This paper has better empirical validation and clearer contribution |
| gJTPyCZmbj (PagFormer) | 4.25 | R1 | This paper is stronger — cleaner ablations, larger datasets, better baselines |
| 7YEXo5qUmN (Organ-DETR) | 4.67 | R1 | This paper is comparable/slightly better — more clinically grounded domain |
| Naiy1jf8UA (MGDC-UNet) | 6.00 | R1 | This paper is weaker — less novelty, unvalidated central claim |
| uJVHygNeSZ (GTA) | 6.25 | R1 | This paper is clearly weaker — less novelty and validation |
| zi3MEZRCqd (Unifying Supervisions) | 4.60 | R2 | This paper is comparable — similar validation scope |
| 33P4evE2ej (DynaMer) | 4.75 | R2 | This paper is comparable — MoE-based, similar weakness profile, but cleaner ablation gains |
| NJxCpMt0sf (M4oE) | 5.75 | R2 | This paper is weaker — less conceptual novelty, unvalidated central framing |
| EtJWnTnqku (MVG) | 5.00 | R2 | This paper is comparable — similar contribution level |

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>